Evidence map›Paper›PMID 32397659›Full record

ArticleMolecules (Basel, Switzerland)2020

Unsymmetrical Bisquinolines with High Potency against

Katherine M Liebman, Steven J Burgess, Bornface Gunsaru, Jane X Kelly, Yuexin Li, Westin Morrill, Michael C Liebman, David H Peyton

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katherine M LiebmanDesignMedix, Inc., Portland, OR 97201, USA.
Steven J BurgessDesignMedix, Inc., Portland, OR 97201, USA.
Bornface GunsaruDepartment of Chemistry, Portland State University, Portland, OR 97207, USA.
Jane X KellyDepartment of Chemistry, Portland State University, Portland, OR 97207, USA.
Yuexin LiPortland VA Research Foundation, Portland, OR 97239, USA.
Westin MorrillDesignMedix, Inc., Portland, OR 97201, USA.
Michael C LiebmanDepartment of Chemistry, Portland State University, Portland, OR 97207, USA.
David H PeytonDesignMedix, Inc., Portland, OR 97201, USA.ORCID 0000-0001-5828-055X

Funding

National Institutes of Health AI114806
6 · The paper itself

Abstract

Quinoline-based scaffolds have been the mainstay of antimalarial drugs, including many artemisinin combination therapies (ACTs), over the history of modern drug development. Although much progress has been made in the search for novel antimalarial scaffolds, it may be that quinolines will remain useful, especially if very potent compounds from this class are discovered. We report here the results of a structure-activity relationship (SAR) study assessing potential unsymmetrical bisquinoline antiplasmodial drug candidates using in vitro activity against intact parasites in cell culture. Many unsymmetrical bisquinolines were found to be highly potent against both chloroquine-sensitive and chloroquine-resistant

Indexed as

AntimalarialsChloroquineErythrocytesHumansInhibitory Concentration 50Malaria, FalciparumPlasmodium falciparumQuinolinesStructure-Activity RelationshipAntimalarialsChloroquineQuinolinesdrug discoverydrug resistancemalariaP. falciparumSARstructure–activity relationship

Identifiers

PMID32397659
PMCPMC7249153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.